Teva Pharma (TEVA) Reports In-Line Q1 EPS; Narrows Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Teva Reports First Quarter 2022 Financial Results
May 3, 2022 7:00 AM EDTRevenues of $3.7 billion GAAP diluted loss per share of $0.86 Non-GAAP diluted EPS of $0.55 Cash flow used in operating activities of $49 million Free cash flow of $117 million 2022 revenue outlook revised lower to reflect ongoing impact of foreign exchange fluctuations; COPAXONE® outlook revised lower mainly to reflect increased competition and foreign exchange fluctuations; all other key components reaffirmed: Revenues of $15.4 - $16.0 billion vs. previous range of $15.6 - $16.2 billion COPAXONE revenues of approximately $750 million vs. previous outlook of approximately $850 million Adjusted EBITDA of $4.7 - $5.0... More
